Income StatementBalance SheetCash FlowSegments
Cigna logo

Cigna Cash Flow Statement

Operating, investing, and financing cash movements

Cigna generated $12.6B in operating cash flow over the trailing twelve months. Based on the Q1 2026 filing.

Net Cash From Operating (TTM)$7.4BNet Cash From Investing (TTM)-$6.2BNet Cash From Financing (TTM)-$8.3BDepreciation And Amortization Cf (TTM)$2.8BNet Change In Cash (TTM)-$3.1B
Latest FilingQ1 2026
Report Date2026-04-30
Market Cap$73.4B
P/E Ratio11.83
ROE15.05%

Investing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Acquisitions, net of cash acquired$32.8M$149.3M$149.3M$149.3M$149.3M—
Payment for (Proceeds from) Other Investing Activity-$77.0M$1.0M$17.0M$6.0M$10.0M$5.0M
Payments For (Proceeds From) Property, Plant, And Equipment$337.0M$327.0M$285.0M$278.0M$322.0M$267.0M
Payments To Acquire Debt And Equity Securities$443.0M$952.0M$560.0M$3.8B$517.0M$362.0M
Payments to Acquire Equity Method Investments$564.0M$92.0M$235.0M$158.0M$617.0M$94.0M
Payments to Acquire Mortgage Notes Receivable$0.0$34.0M$28.0M$55.0M$0.0$39.0M
Payments to Acquire Other Investments$281.0M$475.0M$286.0M$305.0M$350.0M$557.0M
Less: Receipts on loans receivable$109.0M$85.0M$5.0M$108.0M$25.0M$2.0M
Divestiture of businesses, net of cash transferred$521.0M$2.3B——$638.0M$20.0M
Debt securities and equity securities$254.0M$222.0M$331.0M$192.0M$241.0M$185.0M
Debt securities and equity securities$287.0M$94.0M$178.0M$246.0M$264.0M$54.0M
Proceeds from other investments$185.0M$331.0M$100.0M$225.0M$228.0M$426.0M
Net cash from investing activities-$191.0M$1.2B-$797.0M-$4.4B-$420.0M-$637.0M
Proceeds from divestiture of prepaid business$521.0M$2.3B——$638.0M$20.0M

Operating

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Change in inventories$1.6B-$1.5B$791.0M-$334.0M$1.7B-$1.5B
Other working capital changes-$119.0M-$260.0M-$157.0M-$43.0M-$2.0M-$5.0M
Depreciation and amortization$646.0M$674.0M$682.0M$697.0M$722.0M$650.0M
Net cash from operating activities$5.2B$1.9B—$3.4B$6.1B$1.1B
Net income$1.5B$1.4B$1.6B$2.0B$1.3B$1.9B
Gain on sale of business and assets$130.0M$41.0M$0.0$38.0M—$11.0M
Increase (Decrease) in Accounts and Other Receivables—$2.2B$4.2B$513.0M—-$2.2B
Accounts payable and Accrued expenses and other liabilities$2.0B-$1.2B——$3.7B-$988.0M
Increase (Decrease) in Deferred Income Taxes—$216.0M$76.0M-$118.0M-$500.0M$60.0M
Pharmacy and other service costs payable$0.0$135.0M$860.0M$842.0M$31.0M-$4.6B
Increase (Decrease) in Reinsurance Recoverable$127.0M$219.0M$183.0M$135.0M$360.0M-$104.0M
Net investment gains (losses)$0.0-$2.0M$52.0M$26.0M-$100.0M$258.0M

Financing

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Proceeds from issuance of debt—$0.0$0.0$4.5B$0.0—
Repayments of debt—$700.0M$900.0M$43.0M$2.6B$550.0M
Dividends paid$384.0M$412.0M$401.0M$402.0M$396.0M$417.0M
Policyholder contract deposits$46.0M$36.0M$38.0M$39.0M$39.0M$39.0M
Other, net-$94.0M-$211.0M-$144.0M-$157.0M-$112.0M-$158.0M
Repayments Of Notes Payable$0.0$500.0M$500.0M$500.0M$500.0M—
Withdrawal from Contract Holders Funds$48.0M$64.0M$73.0M$64.0M$52.0M$99.0M
Payment of Deferred Purchase Consideration-$94.0M-$211.0M-$144.0M-$157.0M-$112.0M-$158.0M
Noncontrolling interest transactions and other-$94.0M-$211.0M-$144.0M-$157.0M-$112.0M-$158.0M
Net cash from financing activities-$3.2B-$3.7B-$1.3B—-$4.1B-$1.1B
Noncontrolling Interests Activity and Other-$94.0M-$211.0M-$144.0M-$157.0M-$112.0M-$158.0M
Proceeds from issuance of common stock$22.0M$69.0M$72.0M$37.0M$25.0M$57.0M
Repurchases of common stock$2.0B$1.5B$1.1B$0.0$1.0B$0.0

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Effect of exchange rate changes on cash-$26.0M$9.0M$26.0M—$2.0M-$9.0M
Net increase (decrease) in cash$1.7B-$555.0M-$4.0B——-$656.0M
Net change in short-term debt-$768.0M-$891.0M$1.2B-$1.2B-$12.0M-$13.0M

Supplemental

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Interest paid$305.0M$379.0M$301.0M$363.0M$307.0M—
Health care costs payable and other insurance liabilities-$377.0M$1.8B———$739.0M